Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. (Q53626513)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

author name string

Ashkan Emadi

1

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Rawan Faramand

2

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Brandon Carter-Cooper

3

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Seda Tolu

4

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Laurie A Ford

5

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Rena G Lapidus

6

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Meir Wetzler

7

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Eunice S Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Elizabeth A Griffiths

10

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

publication date

27 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

90

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

5

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

E77-9

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Targeting IDH: the next big thing in AML.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Update on the pharmacotherapy for myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

The state of the union on treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Acute myeloid leukemia and myelodysplastic syndromes in older adults

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23965

21 January 2018

Identifiers

10.1002/AJH.23965

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 May 2018

http://europepmc.org/abstract/MED/25651001

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53626513&oldid=1707346437"